FGFR2 and neoplasm: Lirafugratinib is currently being clinically tested in a phase I/II tumour agnostic study of patients with FGFR2 alterations (ReFocus trial), comprising a dose escalation, dose expansion and extension phase (NCT04526106) (Table 2).